MedPath
HSA Approval

SOLMUX PAEDIATRIC SUSPENSION 200 mg/5 ml

SIN12251P

SOLMUX PAEDIATRIC SUSPENSION 200 mg/5 ml

SOLMUX PAEDIATRIC SUSPENSION 200 mg/5 ml

April 3, 2003

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SUSPENSION

ORAL

Medical Information

R05CB03

carbocisteine

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

Amherst Laboratories, Inc

Active Ingredients

CARBOCISTEINE

200 mg/5 ml

Carbocisteine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SOLMUX PAEDIATRIC SUSPENSION 200 mg/5 ml - HSA Approval | MedPath